Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques

Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques

138
Feng, ZidingFred Hutchinson Cancer Research Center
Annexin, LAMR1, PGP
Proteomics
Lung and Upper Aerodigestive Cancers Research Group
2

1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. 1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. 1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.

Aim 1: To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis. Aim 2: To identify additional antigens and antibodies in sera from CARET participants, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, and histologic type. Aim 3: To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.
Natural Array technique

Announcement 09/09/2018

Thank you to everyone who made the 33rd EDRN Steering Committee Meeting a great success. The 34th EDRN Steering Committee Meeting is from March 18-20, 2019 in Nashville, TN. Details available in January, 2019.

Announcement